Looking for a better measure of the benefit in clinical trials: a never-ending journey

Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Biostatistical Unit, Regina Elena National Cancer Institute IRCCS, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Department of Traslational Medicine and Surgery, Università Cattolica del Sacro Cuore, Roma, Italy Correspondence to: Prof. Emilio Bria, MD. Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Department of Traslational Medicine and Surgery, Università Cattolica del Sacro Cuore, L.go A. Gemelli 8, 00168, Roma Italy. Email: emilio.bria@unicatt.it. Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Dr. Jianrong Zhang, MD, MPH (PhD Candidate, Cancer in Primary Care Research Group, Centre for Cancer Research; Department of General Practice, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne; Victorian Comprehensive Cancer Centre, Melbourne, Australia). Comment on: Ben-Aharon O, Magnezi R, Leshno M, et al. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers? Oncologist 2019;24:1469-78.